Alphabet's (GOOG, GOOGL) artificial intelligence-based drug discovery unit Isomorphic Labs said Monday it raised $600 million in its first external funding round to develop its AI drug design engine and support drug candidates into clinical testing.
The investment, led by Thrive Capital with participation from GV and Alphabet, is expected to support AI research, the company said, adding that it has internal drug discovery programs in oncology and immunology, as well as collaborations with Eli Lilly (LLY) and Novartis (NVS).
Isomorphic Labs said it also plans to expand its workforce.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.